Generated Narrative: Citation 264329

url: Citation 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.

identifier: FEvIR Object Identifier/https://fevir.net/FOI/264329, https://pubmed.ncbi.nlm.nih.gov/37024129, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.11

version: 2.0.0-ballot

title: 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.

status: Active

date: 2024-12-19 14:29:51+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

UseContexts

jurisdiction: World

copyright:

approvalDate: 2023-04-10

lastReviewDate: 2023-04-11

author: Computable Publishing®: MEDLINE-to-FEvIR Converter:

classification

type: Citation Source

classifier: MEDLINE

classification

type: MEDLINE Citation Owner

classifier: National Library of Medicine, Index Section

currentState: Medline Citation Status of Medline, PubMed PublicationStatus of epublish

statusDate

activity: PubMed Pubstatus of Medline

period: ?? --> 2023-04-10 06:42:00+0000

statusDate

activity: PubMed Pubstatus of Entrez

period: ?? --> 2023-04-06 20:43:00+0000

statusDate

activity: PubMed Pubstatus of Pubmed

period: ?? --> 2023-04-07 06:00:00+0000

statusDate

activity: PubMed Pubstatus of PMC release

period: ?? --> 2023-04-06

citedArtifact

identifier: https://pubmed.ncbi.nlm.nih.gov/37024129, https://www.ncbi.nlm.nih.gov/pmc//PMC10077111, https://doi.org/10.1136/bmj-2022-074068

Titles

-	Type	Language	Text
*	Primary title	English	Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.

Abstracts

-	Text	Copyright
*	OBJECTIVE: To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options. <AbstractText Label="DESIGN">Systematic review and network meta-analysis. <AbstractText Label="DATA SOURCES">Ovid Medline, Embase, and Cochrane Central up to 14 October 2022. <AbstractText Label="ELIGIBILITY CRITERIA FOR SELECTING STUDIES">Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach. RESULTS: The analysis identified 816 trials with 471 038 patients, together evaluating 13 different drug classes; all subsequent estimates refer to the comparison with standard treatments. Sodium glucose cotransporter-2 (SGLT-2) inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause death; non-steroidal mineralocorticoid receptor antagonists, so far tested only with finerenone in patients with chronic kidney disease, probably reduce mortality (0.89, 0.79 to 1.00; moderate certainty); other drugs may not. The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. Finerenone probably reduces admissions to hospital for heart failure and end stage kidney disease, and possibly cardiovascular death. Only GLP-1 receptor agonists reduce non-fatal stroke; SGLT-2 inhibitors are superior to other drugs in reducing end stage kidney disease. GLP-1 receptor agonists and probably SGLT-2 inhibitors and tirzepatide improve quality of life. Reported harms were largely specific to drug class (eg, genital infections with SGLT-2 inhibitors, severe gastrointestinal adverse events with tirzepatide and GLP-1 receptor agonists, hyperkalaemia leading to admission to hospital with finerenone). Tirzepatide probably results in the largest reduction in body weight (mean difference -8.57 kg; moderate certainty). Basal insulin (mean difference 2.15 kg; moderate certainty) and thiazolidinediones (mean difference 2.81 kg; moderate certainty) probably result in the largest increases in body weight. Absolute benefits of SGLT-2 inhibitors, GLP-1 receptor agonists, and finerenone vary in people with type 2 diabetes, depending on baseline risks for cardiovascular and kidney outcomes (https://matchit.magicevidence.org/230125dist-diabetes). CONCLUSIONS: This network meta-analysis extends knowledge beyond confirming the substantial benefits with the use of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing adverse cardiovascular and kidney outcomes and death by adding information on finerenone and tirzepatide. These findings highlight the need for continuous assessment of scientific progress to introduce cutting edge updates in clinical practice guidelines for people with type 2 diabetes. <AbstractText Label="SYSTEMATIC REVIEW REGISTRATION">PROSPERO CRD42022325948.	© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.

relatesTo

type: cites

classifier: Journal Article

citation:

Gregg EW, Jakicic JM, Blackburn G, et al. Look AHEAD Research Group . Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4:913-21. 10.1016/S2213-8587(16)30162-0.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/27595918/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/27595918

relatesTo

type: cites

classifier: Journal Article

citation:

Palmer SC, Tendal B, Mustafa RA, et al. . Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2021;372:m4573. 10.1136/bmj.m4573.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/33441402/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/33441402

relatesTo

type: cites

classifier: Journal Article

citation:

Li S, Vandvik PO, Lytvyn L, et al. . SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ 2021;373:n1091. 10.1136/bmj.n1091.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/33975892/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/33975892

relatesTo

type: cites

classifier: Journal Article

citation:

Bakris GL, Agarwal R, Anker SD, et al. FIDELIO-DKD Investigators . Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-29. 10.1056/NEJMoa2025845.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/33264825/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/33264825

relatesTo

type: cites

classifier: Journal Article

citation:

Pitt B, Filippatos G, Agarwal R, et al. FIGARO-DKD Investigators . Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021;385:2252-63. 10.1056/NEJMoa2110956.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/34449181/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/34449181

relatesTo

type: cites

classifier: Journal Article

citation:

Rosenstock J, Wysham C, Frías JP, et al. . Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021;398:143-55. 10.1016/S0140-6736(21)01324-6.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/34186022/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/34186022

relatesTo

type: cites

classifier: Journal Article

citation:

Frías JP, Davies MJ, Rosenstock J, et al. SURPASS-2 Investigators . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385:503-15. 10.1056/NEJMoa2107519.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/34170647/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/34170647

relatesTo

type: cites

classifier: Journal Article

citation:

Ludvik B, Giorgino F, Jódar E, et al. . Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 2021;398:583-98. 10.1016/S0140-6736(21)01443-4.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/34370970/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/34370970

relatesTo

type: cites

classifier: Journal Article

citation:

Del Prato S, Kahn SE, Pavo I, et al. SURPASS-4 Investigators . Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 2021;398:1811-24. 10.1016/S0140-6736(21)02188-7.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/34672967/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/34672967

relatesTo

type: cites

classifier: Journal Article

citation:

Dahl D, Onishi Y, Norwood P, et al. . Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA 2022;327:534-45. 10.1001/jama.2022.0078.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35133415/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35133415

relatesTo

type: cites

classifier: Journal Article

citation:

Rydén L, Standl E. After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk. N Engl J Med 2022;387:1136-8. 10.1056/NEJMe2210531.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/36130002/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/36130002

relatesTo

type: cites

classifier: Journal Article

citation:

Nathan DM, Lachin JM, Balasubramanyam A, et al. GRADE Study Research Group . Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med 2022;387:1063-74. 10.1056/NEJMoa2200433.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/36129996/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/36129996

relatesTo

type: cites

classifier: Journal Article

citation:

Nathan DM, Lachin JM, Bebu I, et al. GRADE Study Research Group . Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med 2022;387:1075-88. 10.1056/NEJMoa2200436.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/36129997/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/36129997

relatesTo

type: cites

classifier: Journal Article

citation:

Marx N, Ryden L, Brosius F, et al. . Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. Diabetes Res Clin Pract 2021;177:108870. 10.1016/j.diabres.2021.108870.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/34044026/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/34044026

relatesTo

type: cites

classifier: Journal Article

citation:

Page MJ, McKenzie JE, Bossuyt PM, et al. . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. 10.1136/bmj.n71.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/33782057/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/33782057

relatesTo

type: cites

classifier: Journal Article

citation:

Hutton B, Salanti G, Caldwell DM, et al. . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84. 10.7326/M14-2385.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26030634/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26030634

relatesTo

type: cites

citation:

Guyatt G, Busse J. Methods Commentary: Risk of Bias in Randomized Trials 1. DistillerSR. 2011. https://www.distillersr.com/resources/methodological-resources/risk-of-bias-commentary.

relatesTo

type: cites

classifier: Journal Article

citation:

Levin A, Agarwal R, Herrington WG, et al. participant authors of the International Society of Nephrology’s 1st International Consensus Meeting on Defining Kidney Failure in Clinical Trials . International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney Int 2020;98:849-59. 10.1016/j.kint.2020.07.013.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/32998816/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/32998816

relatesTo

type: cites

classifier: Journal Article

citation:

Rücker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods 2012;3:312-24. 10.1002/jrsm.1058.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26053424/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26053424

relatesTo

type: cites

classifier: Journal Article

citation:

Shi Q, Wang Y, Hao Q, et al. . Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2022;399:259-69. 10.1016/S0140-6736(21)01640-8.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/34895470/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/34895470

relatesTo

type: cites

classifier: Journal Article

citation:

Bhaumik DK, Amatya A, Normand S-L, et al. . Meta-Analysis of Rare Binary Adverse Event Data. J Am Stat Assoc 2012;107:555-67. 10.1080/01621459.2012.664484.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/23734068/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/23734068

relatesTo

type: cites

classifier: Journal Article

citation:

Higgins JPT, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 2012;3:98-110. 10.1002/jrsm.1044.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/26062084/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/26062084

relatesTo

type: cites

classifier: Journal Article

citation:

König J, Krahn U, Binder H. Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons. Stat Med 2013;32:5414-29. 10.1002/sim.6001.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/24123165/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/24123165

relatesTo

type: cites

classifier: Journal Article

citation:

Wiksten A, Hawkins N, Piepho H-P, Gsteiger S. Nonproportional Hazards in Network Meta-Analysis: Efficient Strategies for Model Building and Analysis. Value Health 2020;23:918-27. 10.1016/j.jval.2020.03.010.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/32762994/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/32762994

relatesTo

type: cites

classifier: Journal Article

citation:

Efthimiou O, Rücker G, Schwarzer G, Higgins JPT, Egger M, Salanti G. Network meta-analysis of rare events using the Mantel-Haenszel method. Stat Med 2019;38:2992-3012. 10.1002/sim.8158.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/30997687/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/30997687

relatesTo

type: cites

classifier: Journal Article

citation:

Schandelmaier S, Briel M, Varadhan R, et al. . Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ 2020;192:E901-6. 10.1503/cmaj.200077.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/32778601/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/32778601

relatesTo

type: cites

classifier: Journal Article

citation:

Balshem H, Helfand M, Schünemann HJ, et al. . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6. 10.1016/j.jclinepi.2010.07.015.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/21208779/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/21208779

relatesTo

type: cites

classifier: Journal Article

citation:

Davies AL, Papakonstantinou T, Nikolakopoulou A, Rücker G, Galla T. Network meta-analysis and random walks. Stat Med 2022;41:2091-114. 10.1002/sim.9346.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35293631/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35293631

relatesTo

type: cites

classifier: Journal Article

citation:

Puhan MA, Schünemann HJ, Murad MH, et al. GRADE Working Group . A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 2014;349:g5630. 10.1136/bmj.g5630.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/25252733/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/25252733

relatesTo

type: cites

classifier: Journal Article

citation:

Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. . GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. J Clin Epidemiol 2021;137:163-75. 10.1016/j.jclinepi.2021.03.026.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/33857619/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/33857619

relatesTo

type: cites

classifier: Journal Article

citation:

Zeng L, Brignardello-Petersen R, Hultcrantz M, et al. . GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach. J Clin Epidemiol 2022;150:216-24. 10.1016/j.jclinepi.2022.07.014

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35934265/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35934265

relatesTo

type: cites

classifier: Journal Article

citation:

Brignardello-Petersen R, Florez ID, Izcovich A, et al. GRADE working group . GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework. BMJ 2020;371:m3900. 10.1136/bmj.m3900.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/33177059/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/33177059

relatesTo

type: cites

classifier: Journal Article

citation:

Phillips MR, Sadeghirad B, Busse JW, et al. . Development and design validation of a novel network meta-analysis presentation tool for multiple outcomes: a qualitative descriptive study. BMJ Open 2022;12:e056400. 10.1136/bmjopen-2021-056400.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35688599/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35688599

relatesTo

type: cites

classifier: Journal Article

citation:

Buchan TA, Malik A, Chan C, et al. . Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses. Heart 2021;107:1962-73. 10.1136/heartjnl-2021-319243.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/33833070/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/33833070

relatesTo

type: cites

classifier: Journal Article

citation:

Wright AK, Carr MJ, Kontopantelis E, et al. . Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Diabetes Care 2022;45:909-18. 10.2337/dc21-1113.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35100355/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35100355

relatesTo

type: cites

classifier: Journal Article

citation:

Rossing P, Anker SD, Filippatos G, et al. FIDELIO-DKD and FIGARO-DKD Investigators . Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care 2022;45:2991-8. 10.2337/dc22-0294.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35972218/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35972218

relatesTo

type: cites

classifier: Journal Article

citation:

Sato N, Ajioka M, Yamada T, et al. ARTS-HF Japan study group . A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. Circ J 2016;80:1113-22. 10.1253/circj.CJ-16-0122.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/27074824/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/27074824

relatesTo

type: cites

classifier: Journal Article

citation:

Ruilope LM, Pitt B, Anker SD, et al. . Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant 2023;38:372-83.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/35451488/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/35451488

relatesTo

type: cites

citation:

Bayer. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure (NYHA II-IV) and Left Ventricular Ejection Fraction ≥ 40% (LVEF ≥ 40%). Clinicaltrials.gov. 2022. https://clinicaltrials.gov/ct2/show/NCT04435626.

relatesTo

type: cites

classifier: Journal Article

citation:

Hundemer GL, Sood MM. Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management. Pharmacol Res 2021;172:105835. 10.1016/j.phrs.2021.105835.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/34438065/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/34438065

relatesTo

type: cites

citation:

Eli Lilly and Company. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT). clinicaltrials.gov 2022. https://clinicaltrials.gov/ct2/show/NCT04255433.

relatesTo

type: cites

classifier: Journal Article

citation:

Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2020;16:642-53. 10.1038/s41574-020-0399-8.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/32929230/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/32929230

relatesTo

type: cites

classifier: Journal Article

citation:

Liu J, Li L, Li S, et al. . Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2020;22:1619-27. 10.1111/dom.14075.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/32364674/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/32364674

relatesTo

type: cites

classifier: Journal Article

citation:

Lin C, Zhu X, Cai X, et al. . SGLT2 inhibitors and lower limb complications: an updated meta-analysis. Cardiovasc Diabetol 2021;20:91. 10.1186/s12933-021-01276-9.

Documents

-	Url
*	https://pubmed.ncbi.nlm.nih.gov/33910574/

resourceReference: Identifier: https://pubmed.ncbi.nlm.nih.gov/33910574

publicationForm

publishedIn

type: Periodical

identifier: Electronic ISSN Type/1756-1833, ISOAbbreviation/BMJ, ISSN Linking/0959-8138, Medline Title Abbreviation/BMJ, NLM Unique ID/8900488

title: BMJ (Clinical research ed.)

publisherLocation: England

citedMedium: Internet

volume: 381

articleDate: 2023-04-06

publicationDateText: 2023-Apr-06

language: English

pageString: e074068

publicationForm

citedMedium: Internet without issue

articleDate: 2023-04-06

webLocation

classifier: Abstract

url: https://pubmed.ncbi.nlm.nih.gov/37024129/

webLocation

classifier: DOI Based

url: https://doi.org/10.1136/bmj-2022-074068

classification

type: Publishing Model

classifier: Electronic

classification

type: Chemical

classifier: Sodium-Glucose Transporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists, Glucagon-Like Peptide-1 Receptor

classification

type: MeSH heading

artifactAssessment: ArtifactAssessment: artifact[x] = this resource

classification

type: Publication type

classifier: Meta-Analysis, Systematic Review, Journal Article

classification

type: Knowledge Artifact Type

classifier: Journal Article

artifactAssessment: Classifier added by Computable Publishing LLC

classification

type: Citation subset

classifier: IM

contributorship

complete: true

entry

contributor: Shi Q

forenameInitials: Q

affiliation: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

entry

contributor: Nong K

forenameInitials: K

affiliation: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

entry

contributor: Vandvik PO

forenameInitials: PO

affiliation: Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway.

entry

contributor: Guyatt GH

forenameInitials: GH

affiliation: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

entry

contributor: Schnell O

forenameInitials: O

affiliation: Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany.

entry

contributor: Rydén L

forenameInitials: L

affiliation: Department of Medicine K2, Karolinska Institutet, Stockholm, Sweden.

entry

contributor: Marx N

forenameInitials: N

affiliation: Clinic for Cardiology, Angiology, and Intensive Care Medicine, RWTH Aachen University, University Hospital Aachen, Aachen, Germany.

entry

contributor: Brosius FC

forenameInitials: FC

affiliation: Division of Nephrology, University of Arizona College of Medicine Tucson, Tucson, AZ, USA.

entry

contributor: Mustafa RA

forenameInitials: RA

affiliation: Department of Internal Medicine, Division of Nephrology and Hypertension, University of Kansas, Kansas City, MI, USA.

entry

contributor: Agarwal A

forenameInitials: A

affiliation:

• Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.
• Department of Medicine, McMaster University, Hamilton, ON, Canada.

entry

contributor: Zou X

forenameInitials: X

affiliation: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

entry

contributor: Mao Y

forenameInitials: Y

affiliation: Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China.

entry

contributor: Asadollahifar A

forenameInitials: A

affiliation: Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

entry

contributor: Chowdhury SR

forenameInitials: SR

affiliation: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

entry

contributor: Zhai C

forenameInitials: C

affiliation: Department of Cardiology, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China.

entry

contributor: Gupta S

forenameInitials: S

affiliation: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

entry

contributor: Gao Y

forenameInitials: Y

affiliation:

• Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.
• Evidence-Based Medicine Centre, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.

entry

contributor: Lima JP

forenameInitials: JP

affiliation: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

entry

contributor: Numata K

forenameInitials: K

affiliation: Department of Emergency Medicine, St Marianna University School of Medicine, Kawasaki, Japan.

entry

contributor: Qiao Z

forenameInitials: Z

affiliation: West China School of Medicine, Sichuan University, Chengdu, China.

entry

contributor: Fan Q

forenameInitials: Q

affiliation: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

entry

contributor: Yang Q

forenameInitials: Q

affiliation: Department of Nephrology, National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.

entry

contributor: Jin Y

forenameInitials: Y

affiliation: Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.

entry

contributor: Ge L

forenameInitials: L

affiliation: Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China.

entry

contributor: Yang Q

forenameInitials: Q

affiliation: Evidence-Based Nursing Centre, School of Nursing, Lanzhou University, Lanzhou, China.

entry

contributor: Zhu H

forenameInitials: H

affiliation: Department of Social Medicine and Health Management, School of Public Health, Lanzhou University, Lanzhou, China.

entry

contributor: Yang F

forenameInitials: F

affiliation: Department of Endocrinology and Metabolism, Chengdu Fifth People's Hospital, Chengdu, China.

entry

contributor: Chen Z

forenameInitials: Z

affiliation: Evidence-Based Medicine Centre, Tianjin University of Traditional Chinese Medicine, Tianjin, China.

entry

contributor: Lu X

forenameInitials: X

affiliation: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

entry

contributor: He S

forenameInitials: S

affiliation: Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China.

entry

contributor: Chen X

forenameInitials: X

affiliation: Department of Endocrinology and Metabolism, First People's Hospital of Shuangliu District, Chengdu, China.

entry

contributor: Lyu X

forenameInitials: X

affiliation: Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.

entry

contributor: An X

forenameInitials: X

affiliation: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

entry

contributor: Chen Y

forenameInitials: Y

affiliation: Evidence-Based Social Science Research Centre, School of Public Health, Lanzhou University, Lanzhou, China.

entry

contributor: Hao Q

forenameInitials: Q

affiliation: School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.

entry

contributor: Standl E

forenameInitials: E

affiliation: Forschergruppe Diabetes eV at the Helmholtz Centre, Munich-Neuherberg, Germany.

entry

contributor: Siemieniuk R

forenameInitials: R

affiliation: Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.

entry

contributor: Agoritsas T

forenameInitials: T

affiliation:

• Department of Health Research Methods, Evidence and Impact, McMaster University, ON, Canada.
• Division of General Internal Medicine, Division of Clinical Epidemiology, University Hospitals of Geneva, Geneva, Switzerland.

entry

contributor: Tian H

forenameInitials: H

affiliation: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China.

entry

contributor: Li S

forenameInitials: S

affiliation: Department of Endocrinology and Metabolism, Division of Guideline and Rapid Recommendation, Cochrane China Centre, MAGIC China Centre, Chinese Evidence-Based Medicine Centre, West China Hospital, Sichuan University, Chengdu, China lisheyu@gmail.com.

Generated Narrative: Practitioner #contributor0

identifier: ORCID/0000-0003-4299-5889

name: Qingyang Shi

Generated Narrative: Practitioner #contributor1

name: Kailei Nong

Generated Narrative: Practitioner #contributor2

name: Per Olav Vandvik

Generated Narrative: Practitioner #contributor3

name: Gordon H Guyatt

Generated Narrative: Practitioner #contributor4

name: Oliver Schnell

Generated Narrative: Practitioner #contributor5

name: Lars Rydén

Generated Narrative: Practitioner #contributor6

name: Nikolaus Marx

Generated Narrative: Practitioner #contributor7

name: Frank C Brosius

Generated Narrative: Practitioner #contributor8

name: Reem A Mustafa

Generated Narrative: Practitioner #contributor9

name: Arnav Agarwal

Generated Narrative: Practitioner #contributor10

name: Xinyu Zou

Generated Narrative: Practitioner #contributor11

name: Yunhe Mao

Generated Narrative: Practitioner #contributor12

name: Aminreza Asadollahifar

Generated Narrative: Practitioner #contributor13

name: Saifur Rahman Chowdhury

Generated Narrative: Practitioner #contributor14

name: Chunjuan Zhai

Generated Narrative: Practitioner #contributor15

name: Sana Gupta

Generated Narrative: Practitioner #contributor16

name: Ya Gao

Generated Narrative: Practitioner #contributor17

name: João Pedro Lima

Generated Narrative: Practitioner #contributor18

name: Kenji Numata

Generated Narrative: Practitioner #contributor19

name: Zhi Qiao

Generated Narrative: Practitioner #contributor20

name: Qinlin Fan

Generated Narrative: Practitioner #contributor21

name: Qinbo Yang

Generated Narrative: Practitioner #contributor22

name: Yinghui Jin

Generated Narrative: Practitioner #contributor23

name: Long Ge

Generated Narrative: Practitioner #contributor24

name: Qiuyu Yang

Generated Narrative: Practitioner #contributor25

name: Hongfei Zhu

Generated Narrative: Practitioner #contributor26

name: Fan Yang

Generated Narrative: Practitioner #contributor27

name: Zhe Chen

Generated Narrative: Practitioner #contributor28

name: Xi Lu

Generated Narrative: Practitioner #contributor29

name: Siyu He

Generated Narrative: Practitioner #contributor30

name: Xiangyang Chen

Generated Narrative: Practitioner #contributor31

name: Xiafei Lyu

Generated Narrative: Practitioner #contributor32

name: Xingxing An

Generated Narrative: Practitioner #contributor33

name: Yaolong Chen

Generated Narrative: Practitioner #contributor34

name: Qiukui Hao

Generated Narrative: Practitioner #contributor35

name: Eberhard Standl

Generated Narrative: Practitioner #contributor36

name: Reed Siemieniuk

Generated Narrative: Practitioner #contributor37

name: Thomas Agoritsas

Generated Narrative: Practitioner #contributor38

name: Haoming Tian

Generated Narrative: Practitioner #contributor39

identifier: ORCID/0000-0003-0060-0287

name: Sheyu Li

Generated Narrative: ArtifactAssessment #meshHeading0

artifact: Citation 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.

content

type: components (if present) include qualifier codings

classifier: Adult

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Humans

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Diabetes Mellitus, Type 2

freeToShare: true

component

type: qualifier

classifier: is Major topic

component

type: qualifier

classifier: drug therapy

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Sodium-Glucose Transporter 2 Inhibitors

freeToShare: true

component

type: qualifier

classifier: is Major topic

component

type: qualifier

classifier: adverse effects

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Mineralocorticoid Receptor Antagonists

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: adverse effects

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Network Meta-Analysis

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Glucagon-Like Peptide-1 Receptor

freeToShare: true

component

type: qualifier

classifier: is not a major topic

component

type: qualifier

classifier: therapeutic use

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Quality of Life

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic

content

type: components (if present) include qualifier codings

classifier: Kidney Failure, Chronic

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is Major topic

content

type: components (if present) include qualifier codings

classifier: Heart Failure

freeToShare: true

component

type: qualifier

classifier: is Major topic

component

type: qualifier

classifier: drug therapy

Components

-	Type	Classifier
*	is Major topic	No

content

type: components (if present) include qualifier codings

classifier: Randomized Controlled Trials as Topic

freeToShare: true

Components

-	Type	Classifier
*	qualifier	is not a major topic